68Ga-NODAGA-LM3 (where LM3 is p-Cl-Phe-cyclo (d-Cys-Tyr-d-4-amino-Phe (carbamoyl)-
Lys-Thr-Cys) d-Tyr-NH2) and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 …

Purpose The purpose of this study is to evaluate the diagnostic efficacy of 68 Ga-NODAGA-
LM3 and 68 Ga-DOTA-LM3 and compare them with 68 Ga-DOTATATE in patients with well …

68Ga-DOTA-JR11 is a somatostatin receptor subtype 2–specific antagonist used for PET/CT
imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga …

The current study aimed to compare 68Ga-NODAGA-Cpa-cyclo (d-Cys-amino-Phe-
hydroorotic acid-d-4-amino-Phe (carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga …

Purpose Somatostatin receptor antagonists have shown promise for imaging
neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In …

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst)
receptor antagonists perform better than agonists in detecting neuroendocrine tumors …

The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …

Somatostatin receptor PET tracers such as [68Ga-DOTA, 1-Nal3]-octreotide (68Ga-
DOTANOC) and [68Ga-DOTA, Tyr3]-octreotate (68Ga-DOTATATE) have shown promising …

Purpose Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR)
antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was …